Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Breast (Edinburgh, Scotland)
|
April 24, 2007
The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial
A Rody, T Karn, C Solbach, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin
|
April 5, 2003
[The role of stereotactic 11G vacuum biopsy for clarification of BI-RADS IV findings in mammography]
T Diebold, V Jacobi, E Krapfl, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|
December 17, 2009
C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism
T Weber, G Cammerer, C Schick, et al.
Breast (Edinburgh, Scotland)
|
October 3, 2006
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response
A Rody, T Karn, R Gätje, et al.
Molecular Psychiatry
|
February 13, 2008
Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study
M Reimold, A Batra, A Knobel, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
January 18, 2007
Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype
M Reimold, M N Smolka, G Schumann, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
August 24, 2007
Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study
M Reimold, M N Smolka, A Zimmer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 14, 2010
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial
G von Minckwitz, H Eidtmann, S Loibl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 12, 2022
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
S Loibl, A Schneeweiss, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
B Gerber, S Loibl, H Eidtmann, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Breast (Edinburgh, Scotland)
|
April 24, 2007
The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial
A Rody, T Karn, C Solbach, et al.
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin
|
April 5, 2003
[The role of stereotactic 11G vacuum biopsy for clarification of BI-RADS IV findings in mammography]
T Diebold, V Jacobi, E Krapfl, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|
December 17, 2009
C-11 methionine positron emission tomography/computed tomography localizes parathyroid adenomas in primary hyperparathyroidism
T Weber, G Cammerer, C Schick, et al.
Breast (Edinburgh, Scotland)
|
October 3, 2006
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response
A Rody, T Karn, R Gätje, et al.
Molecular Psychiatry
|
February 13, 2008
Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study
M Reimold, A Batra, A Knobel, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
January 18, 2007
Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype
M Reimold, M N Smolka, G Schumann, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)
|
August 24, 2007
Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study
M Reimold, M N Smolka, A Zimmer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 14, 2010
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial
G von Minckwitz, H Eidtmann, S Loibl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 12, 2022
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
S Loibl, A Schneeweiss, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2013
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
B Gerber, S Loibl, H Eidtmann, et al.
Page
of 5